North America Diltiazem Market

Market Introduction

Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.

North America Diltiazem Strategic Insights

Strategic insights for the North America Diltiazem provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Diltiazem Report Scope

North America Diltiazem Regional Insights

The geographic scope of the North America Diltiazem refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The North America diltiazem market is expected to reach US$ 369.22 million by 2028 from US$ 161.53 million in 2021; it is estimated to grow at a CAGR of 12.5% from 2021 to 2028. Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases, and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.

Diltiazem has potential use in a wide variety of cardiovascular disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death worldwide. CVDs are a major cause of morbidity and affect more people than any other disease. Tobacco consumption, unhealthy diet, and physical inactivity are major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. The Centers for Disease Control and Prevention (CDC) estimated that around 2.7–6.1 million people were suffering from Atrial fibrillation (AFib) in the US in 2019. Every year, over 454,000 hospitalizations and about 158,000 deaths are reported due to AFib in the US. The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan and Apoptin) effectively control the initial ventricular rate in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower.

Furthermore, Diltiazem reduces conduction in the atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. Thus, the increasing prevalence of atrial fibrillation across the globe drives the diltiazem market. Also, the elderly population is more prompt to have atypical presentations, comorbid conditions, and unfavorable outcomes. Structural and functional changes in the cardiovascular system associated with aging are major causes of cardiovascular diseases. Therefore, the rising geriatric population worldwide is leading to an increase in the incidence of cardiovascular disease, bolstering the growth of the diltiazem market.

In North America, the US was highly influenced by the eruption of the COVID-19 pandemic. The COVID-19 pandemic has created technological shifts crucial to providing better care. Given the current pandemic and the need for practicality, the drugs should ideally be FDA approved so they can be rapidly repurposed for COVID-19 treatment. SARS-CoV requires Ca2+ ions for host cell entrance and based on the connection between SARS-CoV and SARS-CoV-2, it is very likely that the exact necessities exist for both viruses. Moreover, as per the recent report of bioRxiv published in July 2020, there is evidence that calcium channel blockers (CCB) inhibit viral infections at the cell entry level. Therefore, treatment with verapamil or Diltiazem inhibits viral infection. Hypertension was among the general comorbidities seen in COVID-19 infected patients. Diltiazem may be helpful to treat hypertension associated with COVID-19. Since the COVID-19 outbreak reached the pandemic status, the entire global supply chain has been affected; however, various pharmaceutical companies are developing vaccines and drugs to combat the pandemic. Therefore, COVID-19 has had a substantial positive impact on the diltiazem market.

Key Market Segments

Based on product, the North America diltiazem market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market. However, the capsules segment is expected to witness the fastest CAGR from 2021 to 2028.

Based on application, the North America diltiazem market was segmented into angina, hypertension, and others. In 2021, the hypertension segment held the largest share of the market. The angina segment is expected to grow at the fastest CAGR during the coming years.

Major Sources and Companies Listed

A few of the primary and secondary sources associated with this report on the North America diltiazem market are the United States Food & Drug Administration (USFDA), Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS), and Canadian Institutes of Health Research (CIHR), among others.

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of North America diltiazem market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the North America diltiazem market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the North America diltiazem market.

NORTH AMERICA DILTIAZEM MARKET SEGMENTATION

By Product Type

• Tablet
• Capsules
• Injection

By

Application

• Hypertension
• Angina
• Others

By Country

• US
• Canada
• Mexico

Company Profiles

• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd
• MYLAN N.V.
• Pfizer Inc.
• Sandoz (Novartis AG)
• Sun Pharmaceutical Industries Ltd
• Hikma Pharmaceuticals PLC
• Zydus Cadila
• Glenmark
• Athenex